Xenon Pharmaceuticals Inc. (XENE)
NASDAQ$35.17-0.43 (-1.21%)
Market Cap
$2.72B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
916 of 924
Rank in Industry
524 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
XENE Insider Trading Activity
XENE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $3,185,855 | 5 | 100 |
Related Transactions
| PATOU GARY | director | 0 | $0 | 1 | $200,947 | $-200,947 |
| AULIN SHERRY | Chief Financial Officer | 0 | $0 | 1 | $770,912 | $-770,912 |
| MORTIMER IAN | PRESIDENT & CEO | 0 | $0 | 3 | $2.21M | $-2.21M |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise …
Insider Activity of Xenon Pharmaceuticals Inc.
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $3.19M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $4.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.
List of Insider Buy and Sell Transactions, Xenon Pharmaceuticals Inc.
| 2025-01-27 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,315 0.0216% | $40.50 | $660,806 | -3.58% | |
| 2025-01-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 22,468 0.0298% | $40.20 | $903,214 | -3.13% | |
| 2025-01-23 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,217 0.0213% | $40.08 | $649,977 | -3.11% | |
| 2024-12-18 | Sale | AULIN SHERRY | Chief Financial Officer | 18,709 0.0256% | $41.21 | $770,912 | -1.03% | |
| 2024-11-22 | Sale | PATOU GARY | director | 4,891 0.0064% | $41.09 | $200,947 | -4.13% | |
| 2024-03-08 | Sale | GAROFALO ELIZABETH A. | director | 2,092 0.0027% | $45.69 | $95,583 | -13.08% | |
| 2024-03-07 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 7,137 0.0095% | $46.28 | $330,290 | -12.81% | |
| 2024-03-07 | Sale | GANNON STEVEN | director | 13,000 0.0173% | $46.28 | $601,615 | -12.81% | |
| 2023-12-14 | Sale | PATOU GARY | director | 7,598 0.0103% | $41.05 | $311,898 | +1.21% | |
| 2023-12-13 | Sale | PATOU GARY | director | 18,978 0.0257% | $39.99 | $758,983 | +4.60% | |
| 2023-08-24 | Sale | Svoronos Dawn | director | 25,000 0.0391% | $38.70 | $967,500 | +4.70% | |
| 2023-06-01 | Sale | PIMSTONE SIMON N. | director | 31,713 0.0485% | $38.82 | $1.23M | +2.56% | |
| 2023-05-31 | Sale | PIMSTONE SIMON N. | director | 62,526 0.0956% | $38.70 | $2.42M | +2.70% | |
| 2023-05-30 | Sale | PIMSTONE SIMON N. | director | 37,006 0.0576% | $39.28 | $1.45M | +3.13% | |
| 2023-05-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 31,655 0.0482% | $41.41 | $1.31M | -4.09% | |
| 2023-03-24 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 700 0.0011% | $35.01 | $24,507 | +10.88% | |
| 2023-03-07 | Sale | PIMSTONE SIMON N. | director | 19,232 0.03% | $36.98 | $711,199 | +6.76% | |
| 2022-11-25 | Sale | PATOU GARY | director | 1,937 0.0032% | $34.79 | $67,390 | +8.14% | |
| 2022-09-02 | Sale | AULIN SHERRY | Chief Financial Officer | 15,355 0.0238% | $39.57 | $607,597 | -3.33% | |
| 2022-08-31 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 8,776 0.0134% | $38.80 | $340,509 | -2.86% |
Total: 75
*Gray background shows transactions not older than one year
Insider Historical Profitability
26.38%
| MORTIMER IAN | PRESIDENT & CEO | 31302 0.0409% | $1.11M | 2 | 4 | +28.18% |
| PATOU GARY | director | 23573 0.0308% | $839,198.80 | 2 | 4 | +22.11% |
| BVF PARTNERS L P/IL | 10 percent owner | 1674468 2.1876% | $59.61M | 10 | 0 | <0.0001% |
| Hayden Michael R | director | 161187 0.2106% | $5.74M | 1 | 0 | +44.6% |
| AZAB MOHAMMAD | director | 57561 0.0752% | $2.05M | 5 | 1 | +72.32% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$193,151,375 | 134 | 8.18% | $2.8B | |
$11,588,217 | 69 | 42.07% | $2.65B | |
$1,376,668 | 53 | 18.46% | $2.38B | |
$1,275,975,557 | 32 | 19.44% | $2.87B | |
Xenon Pharmaceuticals Inc. (XENE) | $5,066,938 | 27 | 26.38% | $2.72B |
XENE Institutional Investors: Active Positions
| Increased Positions | 97 | +42.73% | 6M | +8.44% |
| Decreased Positions | 90 | -39.65% | 4M | -5.74% |
| New Positions | 30 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 623,017 | Sold Out |
| Total Postitions | 234 | +3.08% | 77M | +2.7% |
XENE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $265,793.00 | 9.77% | 7.53M | +607,606 | +8.78% | 2024-12-31 |
| Avoro Capital Advisors Llc | $200,147.00 | 7.36% | 5.67M | 0 | 0% | 2024-12-31 |
| Driehaus Capital Management Llc | $159,667.00 | 5.87% | 4.52M | -75,126 | -1.64% | 2024-12-31 |
| Wellington Management Group Llp | $133,425.00 | 4.91% | 3.78M | -65,836 | -1.71% | 2024-12-31 |
| Braidwell Lp | $102,921.00 | 3.78% | 2.91M | +206,709 | +7.63% | 2024-12-31 |
| Janus Henderson Group Plc | $101,254.00 | 3.72% | 2.87M | +314,363 | +12.32% | 2024-12-31 |
| Commodore Capital Lp | $96,777.00 | 3.56% | 2.74M | +40,000 | +1.48% | 2024-12-31 |
| Polar Capital Holdings Plc | $95,281.00 | 3.5% | 2.7M | +253,012 | +10.35% | 2024-12-31 |
| Capital International Investors | $89,967.00 | 3.31% | 2.55M | -33,962 | -1.32% | 2024-12-31 |
| Capital World Investors | $81,043.00 | 2.98% | 2.29M | -387,000 | -14.43% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.